| Quantity | 20 nmol, 50 nmol, 100 nmol, 200 nmol | 100 μg | 1 | Inquire | 20 nmol, 50 nmol, 100 nmol, 200 nmol |
| Description | The product SIRGT09934WQ-LNA is a type of small interfering RNA (siRNA) that targets GTF2I gene and regulates the expression of gene. The siRNA interferes with the expression of GTF2I gene with complementary nucleotide sequences by degrading mRNA after transcription, preventing translation. The The product SIRGT09934WQ-LNA is a type of small interfering RNA (siRNA) that targets GTF2I gene and regulates the expression of gene. The siRNA interferes with the expression of GTF2I gene with complementary nucleotide sequences by degrading mRNA after transcription, preventing translation. The siRNA is systematically modified with the synthetic RNA-like high affinity nucleotide analogue, Locked Nucleic Acid (LNA), to improve its bio-stability, specificity and efficiency. It has potential applications in RNA interference (RNAi) and gene therapy development.... Read More | This product GTTS-WQ11760MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & Pseudo-UTP. It ecodes the monoclonal antibody that targets CTLA4 gene. The antibody can be applied in Solid tumors research. | Recombinant Norovirus GII.4 Virus-like Particles (NoV GII.4 VLPs) are produced in Insect cell expression system, assembled with VP1 structure protein. VLP is mimicking the native 3D structure of viruses which can elicit strong immune responses. However, VLPs lack viral genomic material which makes Recombinant Norovirus GII.4 Virus-like Particles (NoV GII.4 VLPs) are produced in Insect cell expression system, assembled with VP1 structure protein. VLP is mimicking the native 3D structure of viruses which can elicit strong immune responses. However, VLPs lack viral genomic material which makes them non-infectious, unable to replicate and enhance the safety during manufacture and administration. NoV GII.4 VLPs can be used in the development of NoV GII.4 diagnostics and in vaccine development and R&D (including use as an immunogen).... Read More | This product is a 34 kDa recombinant human Complement C7 protein Antigen with a N-terminal His6-ABP tag expressed in the E.coli. It is available for Antibody Competition. | The product SIRGT02109WQ-2F is a type of small interfering RNA (siRNA) that targets AP2A1 gene and regulates the expression of gene. The siRNA interferes with the expression of AP2A1 gene with complementary nucleotide sequences by degrading mRNA after transcription, preventing translation. The siRNAThe product SIRGT02109WQ-2F is a type of small interfering RNA (siRNA) that targets AP2A1 gene and regulates the expression of gene. The siRNA interferes with the expression of AP2A1 gene with complementary nucleotide sequences by degrading mRNA after transcription, preventing translation. The siRNA is designed with 2_-deoxy-2_-fluoro (2'-F) modification to provide increased stability, increased specificity and reduced immunogenicity. It has potential applications in RNA interference (RNAi) and gene therapy development.... Read More |